1Kerbel RS, Klement G, Pritchard KL, et a. 1 Continuous lowdose anti - angiogenie./metronomic chemotherapy: from the research laboratory into the oncology clinic[J]. Ann Onco,2002,13(1) : 12 -15.
2Gately S, Kerbel R. Antiangiogenie scheduling of lower dose cancer chemotherapy[J]. Cancer J ,2001,7(5) :427 -436.
3Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm thatmore is better [ J ]. Current Ontology, 2009, 16(2) : 7 - 15.
4Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelialcellkinetics and viability predictsurvival in breastcancerpatients receivingmetronomic chemotherapy[ J ]. Blood, 2006, 108 (2) :452 - 459.
5Kamat AA, Kim TJ. Landen CN, et el. Metronomic chemotherapy Enhances the efficacy of antivascuhar therapy in ovarian cancer [ J ]. Cancer Res,2007,67( 1 ) :281 -288.
6Regazzoni S, Pesce G, Marini G, et al. Low - dose continuous intravenous infusion of 5 -fluorouracil for metastatic breast cancer [ J]. Ann 0nco,1996, 7:807-813.
7Coneale P, Cerretani D, Remondo C, et al. A novelmetronomic chemotherapy regimen ofweekly platinum and daily oral etoposide in high - risk non - small cell lung cancer patients [J].Oncol Rep, 2006, 164:133-140:.
8Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low - dosemetronomic oral cyclophosphamide asprimary systemic treatment in elderly breastcancer patients [J]. J Clin Onco,2006, 24(22) : 3623 -3628.
9Franchi F, Grassi P, Ferro D, ctal. Antiangiogenicmetronomic chemotherapy and hyperthermia in the palliation of advanced cancer [J]. Eur J Cancer Care (Engl), 2007, 16 (3) : 258 -262.
